https://pittplusme.org/study/1708
Seborrheic Dermatitis Study
We're sorry. This study is closed and no longer recruiting participants.
STUDY BASICS
Do you have seborrheic dermatitis? You may be able to participate in a study to evaluate the safety and effectiveness of a study drug, called ARQ-154 0.3% foam, in people with moderate-to-severe seborrheic dermatitis after application once per day for 8 weeks. This study involves at least 6 visits over 13 weeks. Compensation is provided.
IRB: 20192397
- A Phase 2a, 8-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-154 Foam 0.3% Administered QD in Subjects with Seborrheic Dermatitis
AGE:
18 and up
DURATION:
13 weeks
VISITS:
6
LOCATION:
Falk Medical Building - Oakland
COMPENSATION:
$52 for each visit
SHARE STUDY
MEET THE RESEARCHER
Laura Ferris
Laura Korb Ferris, MD, PhD, is Professor of Dermatology at the University of Pittsburgh School of Medicine, and is also the Director of Clinical Trials for the Department of Dermatology. Dr. Ferris earned her doctorate in immunology from Johns Hopkins University and her medical degree from the University of Maryland.